Welcome!

iPhone Authors: Onkar Singh, PR.com Newswire, Kevin Benedict, Shelly Palmer, Matthew Lobas

News Feed Item

Free Research Reports on ACAD, ANTH, BPAX, VHC Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY -- (Marketwire) -- 11/26/12 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. The company is on track to release results from their Phase III trial of pimavanserin in patients with Parkinson's disease psychosis later this month.

Find out more about ACADIA Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/ACAD

Anthera Pharmaceuticals Inc. (NASDAQ: ANTH) shares of the biopharmaceutical company have fallen nearly 90 percent year-to-date. The company recently announced that that an abstract of the results from the Phase 2b PEARL-SC clinical study has been accepted as a late-breaking poster presentation at the ACR/ARHP 2012 Annual Scientific Meeting.

Find out more about Anthera Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/ANTH

Biosante Pharmaceuticals Inc. (NASDAQ: BPAX) shares have fallen nearly 60 percent year-to-date. The company earlier this month announced that it has entered into a definitive merger agreement with ANI Pharmaceuticals, Inc., who had net sales of over $16 million in 2011.

Find out more about Biosante Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/BPAX

VirnetX Holding Corporation (NYSE: VHC) shares surged earlier this month after it was reported that the company was awarded a large settlement. A jury has ordered Apple to pay the company $368 million.

Find out more about VirnetX including full access to the free equity report at: www.BedfordReport.com/VHC

Disclaimer: Equity News Circuit is not a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security. A third party, bedfordreport.com has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release.

Contact Information:

Equity News Circuit
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.